Overview

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Status:
Recruiting

Trial end date:
2026-08-07

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).

Phase:

Phase 3

Details

Lead Sponsor:

Actelion

Treatments:

Macitentan